Sugemalimab Plus Chemotherapy Earns UK Approval in First-Line Metastatic NSCLC
The United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency has approved sugemalimab (Cejemly) plus platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) who do not …